Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CINERGY-Pilot Trial: Tacrolimus in Neurologically Deceased Donors to Decrease Kidney Delayed Graft Function
NCT05148715Phase 2Active, not recruiting
- Sponsor
- Université de Sherbrooke
- Start
- Jul 2022
- Primary completion
- Dec 2025
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in ischemia-reperfusion injury (IRI) and delayed graft function (DGF) comparing Tacrolimus with Placebo (2 arms). Primary endpoints: Organ donor accrual rates and Recipient consent rate. Started Jul 2022; status: active, not recruiting.
02
Drugs
tacrolimus
03
Conditions
ischemia-reperfusion injury (IRI)delayed graft function (DGF)
Beyond the preview
Go deeper on NCT05148715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148715.